Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.420
-0.010 (-0.41%)
At close: Feb 3, 2025, 4:00 PM
2.450
+0.030 (1.24%)
After-hours: Feb 3, 2025, 7:53 PM EST
Protalix BioTherapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Protalix BioTherapeutics stock has a target of 15, which predicts an increase of 519.83% from the current stock price of 2.42.
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for Protalix BioTherapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $15 | Strong Buy | Maintains | $10 → $15 | +519.83% | Feb 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +313.22% | Nov 14, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $10 | Strong Buy | Maintains | $7 → $10 | +313.22% | Oct 31, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $7 | Strong Buy | Maintains | $11 → $7 | +189.26% | May 3, 2021 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $11 | Strong Buy | Maintains | $3 → $11 | +354.55% | Jun 8, 2020 |
Financial Forecast
Revenue This Year
53.92M
from 65.49M
Decreased by -17.67%
Revenue Next Year
102.45M
from 53.92M
Increased by 90.00%
EPS This Year
0.02
from 0.09
Decreased by -76.69%
EPS Next Year
0.64
from 0.02
Increased by 3,050.00%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 56.1M | 106.5M | 175.6M |
| Avg | 53.9M | 102.5M | 168.9M |
| Low | 52.3M | 99.4M | 163.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -14.4% | 97.5% | 71.4% |
| Avg | -17.7% | 90.0% | 64.9% |
| Low | -20.1% | 84.4% | 60.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 0.02 | 0.66 | 1.19 |
| Avg | 0.02 | 0.64 | 1.14 |
| Low | 0.02 | 0.62 | 1.11 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -75.8% | 3,174.8% | 86.5% |
| Avg | -76.7% | 3,050.0% | 79.4% |
| Low | -77.4% | 2,956.4% | 74.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.